Symbol="INKT"
AssetType="Common Stock"
Name="Mink Therapeutics Inc"
Description="MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of allogeneic, ready-to-use, invariant natural killer T-cell therapies for treating cancer and other immune-mediated diseases. The company is headquartered in New York, New York."
CIK="1840229"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="149 FIFTH AVENUE, SUITE 500, NEW YORK, NY, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="68844000"
EBITDA="-29288728"
PERatio="None"
PEGRatio="None"
BookValue="-0.13"
DividendPerShare="0"
DividendYield="0"
EPS="-0.68"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.698"
ReturnOnEquityTTM="-4.037"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-0.68"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="7"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="11.5"
EVToRevenue="-"
EVToEBITDA="-3.702"
Beta="None"
num_52WeekHigh="4.32"
num_52WeekLow="0.851"
num_50DayMovingAverage="1.98"
num_200DayMovingAverage="2.165"
SharesOutstanding="34422100"
DividendDate="None"
ExDividendDate="None"
symbol="INKT"
open="2.13"
high="2.13"
low="1.99"
price="2.00"
volume="63506.00"
latest_trading_day="2023-07-07"
previous_close="2.09"
change="-0.09"
change_percent="-4.3062%"
aroon_positive_momentum_days="31"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="31"
Volume_recent_avg="121199"
Change_recent_avg="-0.03"
Delta_recent_avg="0.21"
Variance_recent_avg="0.1"
Change_ratio_recent_avg="-1.79"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="31"
Aroon_momentum_negative="69"
image_negative_thumbnail_id_1="1125"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0158.jpeg"
image_negative_thumbnail_id_2="1146"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0179.jpeg"
image_neutral_thumbnail_id_1="532"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0067.jpeg"
image_neutral_thumbnail_id_2="593"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0006.jpeg"
image_positive_thumbnail_id_1="619"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0089.jpeg"
image_positive_thumbnail_id_2="692"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0016.jpeg"
image_professor_thumbnail_id_1="1172"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0006.jpeg"
image_professor_thumbnail_id_2="1202"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0036.jpeg"
